Lessons Learned: How Avandia is Changing the Way FDA Does Business
This article was originally published in RPM Report
Executive Summary
FDA learned two important lessons from the Avandia debacle. First, the agency needs to be a better communicator—which means telling the public more about what it knows (and doesn’t know) about the safety of marketed products. But Avandia is also leading the agency to rethink what should be required to demonstrate safety, especially for chronic care therapies. Both could mean big changes for industry.
You may also be interested in...
In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?
Regulatory and financial incentives have sparked major investment in orphan drug development, but now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?
In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?
Regulatory and financial incentives have sparked major investment in orphan drug development. One-third of the new molecular entities and novel biologics approved by FDA in the past five years have been orphan drugs. But now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?
Whistleblower Management: Rogue FDA Reviewer Sets Tone to Start Avandia Committee; Forgotten By End
Avandia has been a contentious topic for FDA for six years. The latest advisory committee review highlights how far the agency has come in handling dissent – but also underscores the impact that a lone voice can have on delaying reviews, and prompting damaging headlines.